LB Pharmaceuticals Inc (LBRX)
| Market Cap | 823.59M |
| Revenue (ttm) | n/a |
| Net Income | -38.95M |
| EPS | -2.59 |
| Shares Out | 28.68M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 107,383 |
| Open | 29.27 |
| Previous Close | 29.27 |
| Day's Range | 28.72 - 30.27 |
| 52-Week Range | 13.36 - 33.47 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 45.00 (+56.69%) |
| Earnings Date | May 12, 2026 |
About LBRX
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for LBRX stock is "Strong Buy." The 12-month stock price target is $45.0, which is an increase of 56.69% from the latest price.
News
LB Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
LB-102, a next-generation benzamide antipsychotic, is advancing through late-stage trials for schizophrenia, bipolar depression, and MDD, with strong efficacy, safety, and cognitive benefits. Multiple pivotal readouts are expected through 2029, supporting broad neuropsychiatric expansion.
LB Pharmaceuticals Transcript: AGM 2026
The meeting covered board introductions, two shareholder proposals, and voting. All director nominees were elected and the auditor appointment ratified. No questions were submitted, and voting results will be reported on Form 8-K.
LB Pharmaceuticals to Participate in Upcoming June Investor Events
NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizoph...
LB Pharmaceuticals initiated with a Buy at Clear Street
Clear Street analyst Kaveri Pohlman initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $45 price target The firm is citing its “high conviction” in LB-102, an oral…
LB Pharmaceuticals price target raised to $37 from $31 at Roth Capital
Roth Capital raised the firm’s price target on LB Pharmaceuticals (LBRX) to $37 from $31 and keeps a Buy rating on the shares post the Q1 report. The firm has…
LB Pharmaceuticals reports Q1 EPS (67c), consensus (67c)
“With multiple clinical trials ongoing, our focus is on execution to support several clinical readouts over the next three years that have the potential to unlock tremendous value of LB-102…
LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression
LB Pharmaceuticals Earnings release: Q1 2026
LB Pharmaceuticals released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
LB Pharmaceuticals Quarterly report: Q1 2026
LB Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 12, 2026.
LB Pharmaceuticals Slides: Investor presentation
LB Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
LB Pharmaceuticals initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $45 price target The company is focused on the neuropsychiatry space with a “novel, potentially groundbreaking var...
LB Pharmaceuticals Proxy statement: Proxy filing
LB Pharmaceuticals filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
LB Pharmaceuticals Proxy statement: Proxy filing
LB Pharmaceuticals filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizo...
LB Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference
LB-102, a novel CNS therapeutic, is advancing through fully funded phase III and II trials in schizophrenia, bipolar depression, and adjunctive MDD, with data readouts expected from 2027 to 2029. The drug's differentiated mechanism, strong safety profile, and robust efficacy position it competitively for multiple indications.
Craig-Hallum bullish on LB Pharmaceuticals, initiates with a Buy
As previously reported, Craig-Hallum initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $36 price target centered on LB-102, a Phase 3 oral schizophrenia asset built on a…
LB Pharmaceuticals initiated with a Buy at Craig-Hallum
Craig-Hallum initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $36 price target
LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference
NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizo...
LB Pharmaceuticals files to sell 4.78M shares of common stock for holders
16:06 EDT LB Pharmaceuticals (LBRX) files to sell 4.78M shares of common stock for holders
LB Pharmaceuticals Registration statement: Registration filing
LB Pharmaceuticals filed a registration statement on April 6, 2026, providing details about a securities offering with the SEC.
LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102's Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
Multiple SIRS presentations underscore the potential of LB-102 to address positive, negative, and cognitive symptom domains of schizophrenia Multiple SIRS presentations underscore the potential of LB-...
LB Pharmaceuticals price target raised to $40 from $35 at Stifel
Stifel raised the firm’s price target on LB Pharmaceuticals (LBRX) to $40 from $35 and keeps a Buy rating on the shares. Following an in-line Q4 earnings report, the firm…
LB Pharmaceuticals reports Q4 EPS (45c), consensus (32c)
“2025 was a transformative year for LB. It began with the presentation of positive Phase 2 trial results of LB-102 in acute schizophrenia that support the potential of LB-102 to…
LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Reported positive results from potentially registrational Phase 2 trial ofLB-102 in schizophrenia Advanced LB-102 into late-stage development in multiple indications with initiation ofa pivotal Phase ...
LB Pharmaceuticals Annual report: Q4 2025
LB Pharmaceuticals has published its Q4 2025 annual report on March 26, 2026.